[Molecular mechanisms involved in hormone resistance of prostate cancer]

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Prostate cancer growth is androgen-dependent, mediated by the androgen receptor (AR).
• Androgen pathway blockage is the standard therapy for advanced prostate cancer.
• Cancers often develop resistance to androgen deprivation therapy (ADT), becoming hormone-refractory.

Purpose of the Study:

• To elucidate the mechanisms underlying the development of hormone-refractory prostate cancer.
• To identify key molecular alterations driving AR activation despite ADT.
• To explore alternative AR-independent pathways contributing to cancer progression.

Main Methods:

• Review of established knowledge on AR signaling and prostate cancer.
• Analysis of genetic and molecular factors contributing to therapy resistance.
• Investigation of non-canonical AR activation pathways and AR-independent mechanisms.

Main Results:

• Hormone refractoriness can result from AR gene amplification, mutations, or increased co-activator expression.
• Altered AR activity can be induced by anti-androgens, estrogens, or growth factors.
• The androgen receptor (AR) remains involved in cancer growth even under androgen deprivation.
• Neuroendocrine differentiation represents a partial AR-independent pathway.

Conclusions:

• Understanding the diverse mechanisms of AR activation and AR-independent pathways is crucial.
• This knowledge is essential for developing more effective therapies for hormone-refractory prostate cancer.